Palladia (Toceranib) for Dogs: Uses, Cost & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Palladia is the brand name for toceranib phosphate, an oral prescription anti-cancer medication for dogs. It is a targeted therapy called a tyrosine kinase inhibitor. Instead of working like traditional chemotherapy, it blocks signaling pathways that help some tumors grow and develop a blood supply. In dogs, it is FDA-approved for certain recurrent grade II or III cutaneous mast cell tumors, with or without nearby lymph node involvement.

This medication is most often used under the guidance of your vet or a veterinary oncologist. Palladia can be very helpful for the right patient, but it also has a narrow safety margin, which means monitoring matters. Your vet will usually pair treatment with regular exams, bloodwork, and sometimes urine testing or blood pressure checks.

For many pet parents, one of Palladia's biggest advantages is that it is given by mouth at home. That can reduce repeated hospital visits compared with some injectable cancer treatments. Still, it is a potent anti-cancer drug. Tablets should not be crushed or split unless your vet specifically instructs you to do so, and people handling the medication should use care, especially pregnant family members.

Palladia is labeled for Patnaik grade II or III recurrent skin mast cell tumors in dogs, including cases with regional lymph node involvement. Mast cell tumors are one of the most common skin cancers in dogs, and some of these tumors are driven by abnormal KIT signaling. Because toceranib targets KIT as well as VEGFR and PDGFR pathways, it may slow tumor growth, shrink tumors, or help keep disease stable for a period of time.

Your vet may also discuss off-label use in selected cancers when the expected benefit fits your dog's case. Published veterinary references and clinical use reports describe Palladia being used in some dogs with carcinomas, anal sac adenocarcinoma, thyroid carcinoma, gastrointestinal stromal tumors, melanoma, sarcomas, and metastatic osteosarcoma. Off-label use does not mean inappropriate use. It means the drug is being used outside its FDA label based on oncology judgment and available evidence.

Palladia is not the right fit for every dog with cancer. Some dogs do better with surgery, radiation, injectable chemotherapy, palliative care, or a combination plan. In many cases, your vet is choosing among several reasonable options based on tumor type, stage, your dog's comfort, and your family's goals.

Palladia dosing must be individualized by your vet. The label dose is 3.25 mg/kg by mouth every other day, but many veterinary oncology protocols use lower starting doses around 2.4 to 2.9 mg/kg every 48 hours to improve tolerability while still achieving target inhibition. Dose reductions or temporary treatment breaks are common if side effects develop.

The tablets are given by mouth and may be given with or without food. If your dog vomits when dosed on an empty stomach, your vet may recommend giving future doses with food. Do not crush, split, or handle broken tablets unless your vet specifically directs you. If you miss a dose, call your vet for instructions rather than doubling up.

Monitoring is a major part of safe dosing. Your vet may recommend weekly bloodwork for the first 6 weeks, then less often if your dog is stable. Monitoring often includes a complete blood count, chemistry panel, kidney values, blood proteins, phosphorus, urinalysis, urine protein testing, and sometimes blood pressure. Palladia is also usually paused around surgery because it can delay wound healing.

The most common Palladia side effects are digestive upset and appetite changes. Dogs may develop diarrhea, vomiting, decreased appetite, weight loss, or lethargy. Muscle pain, weakness, lameness, skin or coat changes, and loss of nose pigment can also happen. Mild blood count changes are fairly common, which is one reason your vet will want regular lab monitoring.

More serious problems are less common but important. Palladia can contribute to GI bleeding or ulceration, low white blood cell counts, protein loss, pancreatitis, high blood pressure, bruising or bleeding, nosebleeds, blood clots, and delayed healing after surgery. Rarely, severe complications such as GI perforation have been reported.

Call your vet promptly if your dog has bloody stool, black tarry stool, repeated vomiting, refusal to eat, marked weakness, bruising, bleeding, leg swelling, trouble breathing, or sudden behavior changes. See your vet immediately if those signs are severe. Many dogs can stay on Palladia successfully, but side effects often need fast dose adjustment, a treatment pause, or supportive care.

Palladia has several important interaction and safety concerns, so your vet should review every medication, supplement, and herbal product your dog receives. Drugs that may need extra caution include NSAIDs such as carprofen or meloxicam, because combining them with Palladia may increase the risk of gastrointestinal ulceration or bleeding.

Other medications that can matter include CYP3A4 inhibitors, certain other anti-cancer drugs, and calcitriol. Combination cancer protocols are sometimes used in oncology, but they require careful planning because the risk of low white blood cell counts and GI side effects can increase. Live or modified-live vaccines are also generally avoided while a dog is receiving this medication.

Palladia should also be used cautiously in dogs with liver disease, kidney disease, GI disease, bone marrow suppression, active infection, or recent surgery. It is not recommended for breeding, pregnant, or lactating dogs, and labeled use excludes dogs under 24 months of age or under 11 pounds. If your dog needs surgery or starts a new medication, tell your vet before the next dose.